Zomagen Biosciences Ltd. clinical trials
Acquired by Eli Lilly and Company, Mar 4, 2026 · source ↗
The registry lists 4 studies whose lead sponsor is Zomagen Biosciences Ltd. 1 is recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 9, 2026.
- 4studies on the registry
- 1open to participants now
- 1reach primary completion within a year
Before and after it joined Eli Lilly and Company
- First submitted before Zomagen Biosciences Ltd. became part of Eli Lilly and Company
- 4
- First submitted after Zomagen Biosciences Ltd. became part of Eli Lilly and Company
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Coming up
1 of Zomagen Biosciences Ltd.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- 1OOct
- NNov
The study
- Oct 2027An Open-Label Pilot Study of VTX2735 in Recurrent PericarditisNCT06836232
Add it to your calendar (.ics) → With an account.
All 4 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 23
- 24
- 225
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Zomagen Biosciences Ltd.4 studies
Something wrong with this grouping? Tell us on the Eli Lilly and Company page.
Studies
Recruiting first, then most recently updated. Showing 4 of 4. All Eli Lilly and Company studies →
- An Open-Label Pilot Study of VTX2735 in Recurrent PericarditisRecruitingNCT06836232Phase 2
Sponsor listed in the registry: Zomagen Biosciences Ltd. · First submitted before Zomagen Biosciences Ltd. became part of Eli Lilly and Company
- Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in ObesityCompletedNCT06771115Phase 2
Sponsor listed in the registry: Zomagen Biosciences Ltd. · First submitted before Zomagen Biosciences Ltd. became part of Eli Lilly and Company
- Phase 2a Study of VTX3232 in Parkinson's DiseaseCompletedNCT06556173Phase 2
Sponsor listed in the registry: Zomagen Biosciences Ltd. · First submitted before Zomagen Biosciences Ltd. became part of Eli Lilly and Company
- A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic SyndromeCompletedNCT05812781Phase 2
Sponsor listed in the registry: Zomagen Biosciences Ltd. · First submitted before Zomagen Biosciences Ltd. became part of Eli Lilly and Company